Publications

Haraoui et al. conducted a subgroup analysis of the CANTORAL study, showing that tofacitinib effectiveness was similar in patients with or without CV risk enrichment. However, AEs, particularly in older patients (≥65 years), were more frequent in the CV+ cohort. These findings highlight the need for tailored CV risk management when treating RA with tofacitinib.

The CANTORAL study assessed safety, persistence, and effectiveness of tofacitinib in a real-world Canadian RA population with CV risk enrichment stratification. Effectiveness measures included CDAI-defined low disease activity/remission, which was comparable between CV+ and CV− groups, while safety data indicated higher AE incidences in the CV+ cohort.